Live-cell Analysis for Neuroscientists

January 18, 2019

Stem cell technologies using iPSCs allow researchers to create differentiated neurons and support cells to study the human brain and nervous system functions, circumventing several challenges in neurobiology research. These technologies, however, require considerable effort to build and validate cellular bioassays that represent native human physiology or pathophysiology. Live-cell analysis techniques are well-suited to the requirements of neuroscientists working with either basic or advanced cell models; live-cell analysis allows generation of data throughout the experimental workflow and time-lapse imaging right within the cell incubator for complete environmental control.

Spotlight

Amarant Groep

The ‘Amarant Groep’ is a large healthcare organisation in the province Noord-Brabant, the Netherlands, providing care to clients in every stage of life. The client perspective is always central. All efforts and innovations are focused on the clients doing it themselves, get involved and their quality of life. The Amarant Groep is the total of the following three brand names.

OTHER WHITEPAPERS
news image

Innovative strategies to maintain product integrity in Biologic andBiosimilar clinical studies

whitePaper | August 7, 2022

The number of biologic new molecular entities approved by the FDA has increased over the last five years indicates a growing focus on biosimilar.

Read More
news image

6 Strategies to Stimulate Patient Engagementin Rehab Therapy

whitePaper | August 25, 2022

Patient engagement has become a measure of healthcare analytics that many in rehab therapy have sought to quantify.

Read More
news image

GMP Grade PMSF and Protease Inhibitors

whitePaper | February 23, 2023

Phenylmethylsulfonyl fluoride, better known as PMSF, is a small molecule serine protease inhibitor used to prevent unwanted proteolysis.

Read More
news image

Healthcare system readiness for the adoption of advanced therapies: learnings from the introduction of CAR T cell therapies in the UK

whitePaper | September 17, 2021

The adoption of CAR T therapies in the UK NHS is a success story, especially seen in relation to the experience in many other countries. The UK NHS showed itself to be agile, and responsive to addressing the unique challenges these therapies present, which facilitated access to patients earlier than in many other countries. (including delivery centre selection, development of service specifications, collaboration with manufacturers throughout the preparation phase for adoption, establishment of national multidisciplinary CAR T team to ensure equity of access and prioritization of resources (where needed)).

Read More
news image

Early engagement and regulatory considerations for biotech

whitePaper | March 24, 2023

Biotechnology companies are at the epicenter of innovative drug development, with discoveries spanning from small molecules, large molecules, and biologics to genomic medicines and first-inclass immunotherapies.

Read More
news image

Are Nitrosamines aConcern for BiologicManufacturers?

whitePaper | July 12, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk. This article provides an assessment of nitrosamine contamination specifically in biologics and contrasts the potential risks between these product types.

Read More

Spotlight

Amarant Groep

The ‘Amarant Groep’ is a large healthcare organisation in the province Noord-Brabant, the Netherlands, providing care to clients in every stage of life. The client perspective is always central. All efforts and innovations are focused on the clients doing it themselves, get involved and their quality of life. The Amarant Groep is the total of the following three brand names.

Events